PhD, MSc, BSc
Senior Clinical Trials Project Manager
I joined OVG in December 2021 as a Project manager to ensure that the clinical trials are delivered on time, within budget and in compliance with the regulatory requirements. I manage the set up and delivery of non-commercial and commercial, University of Oxford- or externally-sponsored, adult and paediatric vaccine clinical trials.
Before joining OVG, from 2008 till 2013 I was a scientist at the Cell Differentiation and Tumorigenesis research group headed by Prof Achim Leutz and was awarded a PhD fellowship from the International PhD Program at Max Delbruck Center for Molecular Medicine and Humboldt University, Berlin, Germany.
After completing my PhD, I worked as a postdoctoral researcher at Prof Paresh Vyas research group Biology and Treatment of Human Myeloid Cancers at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine. I worked on research projects aiming to understand the mechanisms of blood cell development and how these mechanisms get deregulated in leukaemia.
A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.
Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
Juban G. et al, (2021), Haematologica, 106, 1106 - 1119
Mechanisms of Response and Resistance to AML Therapies.
Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.
Lachowiez CA. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38
C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.
Di Genua C. et al, (2020), Cancer Cell, 37, 690 - 704.e8